RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer: experimental drug enters final testing
Disease control Recruiting nowThis study is testing a new drug called QLS32015 for people with multiple myeloma that has come back or stopped responding to other treatments. It will compare the new drug against two standard treatment combinations to see which is better at controlling the cancer and is safer. …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing a new drug called F182112, given in different combination schedules, for people with multiple myeloma that has come back or stopped responding to prior treatments. It aims to see how well the treatment works and how safe it is. The study will enroll about 90…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Double-Target cell therapy tested for stubborn blood cancer
Disease control Recruiting nowThis is an early-stage study testing a new type of cell therapy called O&D-001 for adults with multiple myeloma that has come back or stopped responding to standard treatments. The therapy involves modifying a patient's own immune cells to recognize and attack two specific target…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
First patients receive experimental Triple-Action drug for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is the first time researchers are testing a new experimental drug called JNJ-79635322 in people. The main goal is to find a safe dose for future studies. The trial is for adults with advanced multiple myeloma or AL amyloidosis, two serious blood disorders, who have already t…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether a new drug called QLS32015 works better when combined with other existing myeloma drugs. It is for people whose multiple myeloma has come back or is no longer responding to their current treatments. The main goals are to see if the combinations can s…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New Two-Pronged attack tested for stubborn blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination (cevostamab and elranatamab) for people with multiple myeloma that has returned or stopped responding to other treatments. The main goals are to see what side effects occur and to find the ri…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New hope for Tough-to-Treat blood cancer: major trial tests Next-Generation therapy
Disease control Recruiting nowThis large study aims to see if a new drug combination works better than the current standard treatment for people with multiple myeloma that has returned or stopped responding to previous therapies. Researchers will compare two different three-drug combinations in 810 patients w…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
First patients to test new hope for stubborn blood cancer
Disease control Recruiting nowThis is the first study in people to test a new drug called JNJ-87562761. It aims to find a safe dose and see how well it works for adults with multiple myeloma, a blood cancer, that has come back or stopped responding to other treatments. The main goal is to check for side effec…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Moderna tests mRNA shot to fight tough blood cancer
Disease control Recruiting nowThis study is testing a new mRNA-based therapy called mRNA-2808 for people with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find a safe dose and see how well the body handles the treatment. Researchers will also check if…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:42 UTC
-
New Triple-Targeting antibody enters human testing for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial is testing a new experimental antibody called SIM0500 in adults with advanced multiple myeloma that has returned or stopped responding to all standard treatments. The study aims to find a safe dose and see if the treatment shows early signs of fighting the …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New immune therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis is the first study in people to test a new drug called YKST02 for multiple myeloma, a type of blood cancer, that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. The drug is designed to h…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC